Table 1.
Oral PrEP Efficacy Trial Characteristics, Including Transgender Enrollment
| Trial |
Primary
Population |
Setting(s) | Enrollment |
Trans Women
Enrollment (%) |
|---|---|---|---|---|
|
| ||||
| TFV Phase II* | Women | Cameroon, Ghana, Nigeria |
936 | 0 (0%) |
| iPrEx | MSM and TGW |
Ecuador, Brazil, Peru, South Africa, Thailand, USA |
2,499 | 29 (1.2%) |
| FEM-PrEP* | Women | Kenya, South Africa, Tanzania |
1,951 | 0 (0%) |
| TDF2 | HSM and HSW |
Botswana | 1,200 | 0 (0%) |
| PartnersPrEP | SDC | Kenya, Uganda | 4,747 (Couples) | 0 (0%) |
| VOICE* | Women | South Africa, Uganda, Zimbabwe |
5,029 | 0 (0%) |
| Bangkok Tenofovir Study | PWID | Thailand | 2,413 | 0 (0%) |
|
| ||||
| Total | 18,775 | 29 (0.2%) | ||
Abbreviations: Men who have sex with men (MSM), transgender women (TGW), heterosexual men (HSM), heterosexual women (HSW), serodiscordant couples (SDC), people who inject drugs (PWID)
*
Enrolled only cisgender women